GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirati Therapeutics Inc (NAS:MRTX) » Definitions » Shiller PE Ratio

Mirati Therapeutics (Mirati Therapeutics) Shiller PE Ratio : (As of May. 14, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Mirati Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mirati Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Mirati Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirati Therapeutics Shiller PE Ratio Chart

Mirati Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mirati Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mirati Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Mirati Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirati Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirati Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Mirati Therapeutics's Shiller PE Ratio falls into.



Mirati Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Mirati Therapeutics's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Mirati Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-2.49/129.8595*129.8595
=-2.490

Current CPI (Sep. 2023) = 129.8595.

Mirati Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -0.600 98.326 -0.792
201403 -1.010 99.695 -1.316
201406 -0.820 100.560 -1.059
201409 -0.720 100.428 -0.931
201412 -0.770 99.070 -1.009
201503 -0.770 99.621 -1.004
201506 -0.950 100.684 -1.225
201509 -1.110 100.392 -1.436
201512 -0.960 99.792 -1.249
201603 -1.130 100.470 -1.461
201606 -1.110 101.688 -1.418
201609 -0.970 101.861 -1.237
201612 -0.990 101.863 -1.262
201703 -0.730 102.862 -0.922
201706 -0.740 103.349 -0.930
201709 -0.650 104.136 -0.811
201712 -0.670 104.011 -0.837
201803 -0.510 105.290 -0.629
201806 -0.940 106.317 -1.148
201809 -0.850 106.507 -1.036
201812 -0.870 105.998 -1.066
201903 -1.170 107.251 -1.417
201906 -1.260 108.070 -1.514
201909 -1.380 108.329 -1.654
201912 -1.830 108.420 -2.192
202003 -2.020 108.902 -2.409
202006 -1.890 108.767 -2.257
202009 -1.960 109.815 -2.318
202012 -2.080 109.897 -2.458
202103 -2.670 111.754 -3.103
202106 -3.230 114.631 -3.659
202109 -1.550 115.734 -1.739
202112 -3.720 117.630 -4.107
202203 -3.400 121.301 -3.640
202206 -3.180 125.017 -3.303
202209 -3.090 125.227 -3.204
202212 -3.510 125.222 -3.640
202303 -3.180 127.348 -3.243
202306 -3.040 128.729 -3.067
202309 -2.490 129.860 -2.490

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mirati Therapeutics  (NAS:MRTX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Mirati Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Mirati Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mirati Therapeutics (Mirati Therapeutics) Business Description

Traded in Other Exchanges
Address
3545 Cray Court, San Diego, CA, USA, 92121
Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.
Executives
Jamie Christensen officer: Sr. Vice President, Chief Scie C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Benjamin Hickey officer: EVP, Chief Commercial Officer C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Aaron Ondrey officer: Interim CFO 3545 CRAY COURT, SAN DIEGO CA 92121
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Christopher Fuglesang other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Shehan Bharatha Dissanayake other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Faheem Hasnain director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John B Moriarty officer: Chief Legal Officer ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Laurie Stelzer officer: CFO 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121

Mirati Therapeutics (Mirati Therapeutics) Headlines

From GuruFocus